Trevena to Present at the 2019 Cantor Global Healthcare Conference
September 27 2019 - 7:00AM
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused
on the development and commercialization of novel medicines for
patients with Central Nervous System (CNS) conditions, today
announced that its management team will present at the 2019 Cantor
Global Healthcare Conference sponsored by Cantor Fitzgerald, to be
held at the InterContinental New York Barclay Hotel in New York
City on Friday, October 4, 2019 at 8:20 a.m. EST.
A live audio webcast and archived replay of the presentation
will be available on the Company’s investor relations website at
https://investors.trevena.com/. Following the conclusion of
the presentation, the webcast will be available for replay for 30
days.
For more information about the conference, or to
schedule a one-on-one meeting with the Company’s management, please
contact KCSA Strategic Communications at Trevena@kcsa.com, or send
an email to corporateaccess@cantor.com (Cantor Fitzgerald).
About Trevena
Trevena, Inc. is a biopharmaceutical company
focused on the development and commercialization of novel medicines
for patients with Central Nervous System conditions. The
Company has four novel and differentiated investigational drug
candidates, including IV oliceridine, for the management of
moderate-to-severe acute pain in hospitals, TRV250 for the acute
treatment of migraine, and TRV734 for maintenance treatment of
opioid use disorder. The Company has also identified TRV045, a
novel S1P receptor modulator that may offer a new, non-opioid
approach to managing chronic pain.
For more information, please contact:
Investor Contact:Valter Pinto / Allison
SossKCSA Strategic CommunicationsPhone: 212-896-1254 /
212-896-1267Email: IR@trevena.com
Company Contact:Bob Yoder, SVP and Chief
Business OfficerTrevena, Inc.Phone: 610-354-8840
Trevena (NASDAQ:TRVN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Trevena (NASDAQ:TRVN)
Historical Stock Chart
From Apr 2023 to Apr 2024